中文摘要：

目的：研究谷胱甘肽硫转移酶（GSTs）基因多态性与环磷酰胺在难治性肾病综合征的不良反应关系。方法：运用等位基因特异性PCR（ASPCR）和PCR-限制性片段长度多态性（PCR-RFLP）的方法分析谷胱甘肽硫转移酶基因型；参照SFDA的不良反应分析标准分析环磷酰胺在难治性肾病综合征的不良反应。结果：骨髓抑制组和胃肠道反应组合有GSTP1（I／V或V／V）的机率高于无骨髓抑制组和无胃肠道反应组，GSTP1（I／V或V／V）组患者发生骨髓抑制和胃肠道反应机率高于GSTP1（I／I）组患者。结论：环磷酰胺治疗前检测GSTs基因多态性有助于避免骨髓抑制和胃肠道反应的发生。

英文摘要：

OBJECTIVE To study the relation of glutathione S-transferase genotype with the adverse drug reaction of cyclophosphamide in nephritic syndrome patients. METHODS Glutathione S-transferase polymorphisms were analyzed by ASPCR and the PCR-RFLP method, Refractory nephrotic syndrome adverse reactions of cyclophosphamide were analyzed using SFDA ADR criteria. RESULTS The frequency of gastrointestinal reactions containing GSTP1 （I/V or V/V） of marrow suppression is higher than those without gastrointestinal tract Reaction Group and without marrow suppression group（I/V or V/V）. The frequency of marrow suppression and gastric intestinal reaction of GSTP1 （I/V or V/V）group is higher than GSTP1 （I/I） group. CONCLUSION Patients with mutation alleles of GSTP1 are likely to have bone marrow suppression and gastrointestinal reactions. To detect the glutathione S-transferase genotype before using cyclophosphamide is significant to improve the therapeutic safety.